I Drank Beet Juice Every Day for a Month—It Had This Unexpected Effect
Disclaimer: I am a caffeine fiend. I drink so much coffee that my local barista regularly chides me, reminding me 'it's not good for your heart' to start the day with a triple-shot flat white before 6 a.m.
But when I became pregnant—and had to limit my daily caffeine intake to around 200 mg a day (or two single-shot coffees)—it was a struggle to say the least. Pre-pregnancy, I also indulged in nootropics, Diet Coke, and caffeine-infused anything to help me get through the day. But now? It was all a no. And I was flat out tired.
That's when I stumbled upon a juice called the 'Fatigue Fighter' made of beets, apples, oranges, celery, and ginger. I was willing to give basically anything a try, and quickly downed an entire container. Delicious. But it wasn't until my energy soared that I became a believer. Read on for all the reasons that maybe you should give it a try, too.
What are the benefits of drinking beet juice?
I've waxed lyrical about my personal experience with beet juice, but what are the actual health benefits? Evelina Sabonaityte, MD and clinical nutritionist, claims that beet juice is 'a nutrient-packed elixir.' Here are some of the benefits of beet juice, according to Evelina and Dr Katy Kasraie, one of the general practitioners at The London General Practice.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Bloomberg
3 hours ago
- Bloomberg
UK Heat Wave Could Claim Nearly 600 Lives This Week, Experts Warn
Scientists have warned the elderly and other vulnerable groups in the UK are at risk of heat-related deaths this weekend, as a new study shows recent high temperatures could claim 570 lives in just over four days. Researchers at the London School of Hygiene & Tropical Medicine and Imperial College London published on Saturday a real-time analysis calculating the number of heat-related deaths expected from Thursday to Sunday.
Yahoo
4 hours ago
- Yahoo
The assisted dying debate has been politics – but not as we know it
The House of Commons is a place defined by confrontation where political battles play out and engage more actively with their constituents. But the atmosphere could not have been more different on Friday, as those on both sides of the assisted dying debate listened respectfully, almost solemnly, to one another in the final hours before . As MPs headed for the division lobbies, the bill's supporters seemed confident but nervous. Read more: When the voting was completed and the result imminent, a long and profound silence fell over the House. From the press gallery, it seemed that the entire Commons was holding its breath together, collectively aware of the historic moment we were all about to witness, whatever the outcome. The woman at the centre of this seismic moment, the bill's sponsor Kim Leadbeater, braced herself as the result came in. Many months of pressure and responsibility appeared to be lifted from her shoulders as the win was announced and colleagues gathered to commend her efforts. Throughout the process this been politics but not as we know it, with party divisions put aside and MPs asked to search their own consciences and come to their own conclusions. It has created a more collaborative atmosphere in parliament and encouraged MPs to engage more actively with their constituents. In the end there was still anger, frustration and disappointment among those who were against the law change, either on principle or because they believed the legislation was flawed. And of course, politics will go back to being combative and voices in the Commons will be raised once again. But for a brief period, historic change was calmly ushered in. The challenge for the proponents now is to take the legislation through the next phases and deliver it with the same smoothness and determination.
